The MIND Randomized Controlled Trial: An Intervention to Improve Neural Speech Processing and 2-Year Language Outcomes of Infants Born Preterm.

J PediatrJun 5, 2026 (epub)
Clinical ResearchPediatricsOpen access

Nathalie L Maitre, Caitlin P Kjeldsen, Arnaud Jeanvoine et al.

✦ AI-curated · Sources linked

In 30 seconds

The MIND randomized controlled trial evaluated a multisensory intervention involving caregivers' voices to enhance neural speech processing in preterm infants. Conducted in a neonatal intensive care unit, the study found that infants receiving the MIND intervention demonstrated greater neural speech-sound differentiation compared to those receiving enhanced standard care, with significant effects on language outcomes at 2 years.

Key findings

  • Infants receiving MIND showed greater neural speech-sound differentiation compared to controls (F ranging 5.33-7.87; P ranging .03 to .04).
  • MIND intervention resulted in small-to-medium size effects on language outcomes mediated by EEG (R 2 ranging 0.39-0.57; P ranging .05 to <.001).
  • 100 infants completed the MIND intervention, while 98 completed enhanced standard care.

Why it matters

This study highlights the potential of parent-supported interventions in improving neurodevelopmental outcomes for preterm infants, emphasizing the importance of caregiver involvement in early developmental support.

Source

PubMed · PMID 42250747Free full text on PubMed Central

Published in J Pediatr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.